202 related articles for article (PubMed ID: 30431583)
1. A nonrandomized controlled study of sacral giant cell tumors with preoperative treatment of denosumab.
Yang Y; Li Y; Liu W; Xu H; Niu X
Medicine (Baltimore); 2018 Nov; 97(46):e13139. PubMed ID: 30431583
[TBL] [Abstract][Full Text] [Related]
2. Retrospective cohort study of 68 sacral giant cell tumours treated with nerve-sparing surgery and evaluation on therapeutic benefits of denosumab therapy.
Lim CY; Liu X; He F; Liang H; Yang Y; Ji T; Yang R; Guo W
Bone Joint J; 2020 Feb; 102-B(2):177-185. PubMed ID: 32009426
[TBL] [Abstract][Full Text] [Related]
3. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
[TBL] [Abstract][Full Text] [Related]
4. Ultra-Short Course of Neo-Adjuvant Denosumab for Nerve-Sparing Surgery for Giant Cell Tumor of Bone in Sacrum.
Liang H; Liu X; Yang Y; Guo W; Yang R; Tang X; Yan T; Li Y; Tang S; Li D; Qu H; Dong S; Ji T; Du Z; Zang J
Spine (Phila Pa 1976); 2022 May; 47(9):691-701. PubMed ID: 34961753
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
[TBL] [Abstract][Full Text] [Related]
6. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.
Agarwal MG; Gundavda MK; Gupta R; Reddy R
Clin Orthop Relat Res; 2018 Sep; 476(9):1773-1782. PubMed ID: 30794215
[TBL] [Abstract][Full Text] [Related]
7. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
[TBL] [Abstract][Full Text] [Related]
8. Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review.
Tsukamoto S; Tanaka Y; Mavrogenis AF; Kido A; Kawaguchi M; Errani C
Clin Orthop Relat Res; 2020 May; 478(5):1076-1085. PubMed ID: 31794487
[TBL] [Abstract][Full Text] [Related]
9. [Clinical, radiologic and pathologic features of giant cell tumor of bone treated with denosumab].
Gong LH; Liu WF; Ding Y; Zhang W; Yang YK; Yu F; Wong GQ; Huang XY; Niu XH
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):449-454. PubMed ID: 29886590
[No Abstract] [Full Text] [Related]
10. Combining of serial embolization and denosumab for large sacropelvic giant cell tumor: Case report of 3 cases.
Ji T; Yang Y; Wang Y; Sun K; Guo W
Medicine (Baltimore); 2017 Aug; 96(33):e7799. PubMed ID: 28816971
[TBL] [Abstract][Full Text] [Related]
11. Giant cell tumour of the bone treated with denosumab: How has the blood supply and oncological prognosis of the tumour changed?
Niu X; Yang Y; Wong KC; Huang Z; Ding Y; Zhang W
J Orthop Translat; 2019 Jul; 18():100-108. PubMed ID: 31508313
[TBL] [Abstract][Full Text] [Related]
12. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
Scoccianti G; Totti F; Scorianz M; Baldi G; Roselli G; Beltrami G; Franchi A; Capanna R; Campanacci DA
Clin Orthop Relat Res; 2018 Sep; 476(9):1783-1790. PubMed ID: 30778015
[TBL] [Abstract][Full Text] [Related]
13. Giant cell tumour of bone in the denosumab era.
van der Heijden L; Dijkstra PDS; Blay JY; Gelderblom H
Eur J Cancer; 2017 May; 77():75-83. PubMed ID: 28365529
[TBL] [Abstract][Full Text] [Related]
14. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
[TBL] [Abstract][Full Text] [Related]
15. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
[TBL] [Abstract][Full Text] [Related]
16. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
Ueda T; Morioka H; Nishida Y; Kakunaga S; Tsuchiya H; Matsumoto Y; Asami Y; Inoue T; Yoneda T
Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
[TBL] [Abstract][Full Text] [Related]
17. Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis.
Chen X; Li H; Zhu S; Wang Y; Qian W
BMC Musculoskelet Disord; 2020 Apr; 21(1):256. PubMed ID: 32312263
[TBL] [Abstract][Full Text] [Related]
18. Outcome of re-operation for local recurrence following pre-operative denosumab administration and curettage for giant cell tumour of bone with difficult joint preservation.
Tsukamoto S; Hindiskere S; Honoki K; Mavrogenis AF; Tanaka Y; Chinder PS; Donati DM; Errani C
Int Orthop; 2023 Jan; 47(1):265-273. PubMed ID: 36282294
[TBL] [Abstract][Full Text] [Related]
19. Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection?
Sambri A; Medellin MR; Errani C; Campanacci L; Fujiwara T; Donati D; Parry M; Grimer R
J Orthop Sci; 2020 May; 25(3):513-519. PubMed ID: 31155442
[TBL] [Abstract][Full Text] [Related]
20. Role of denosumab before resection and reconstruction in giant cell tumors of bone: a single-centered retrospective cohort study.
Sahito B; Ali SME; Kumar D; Kumar J; Hussain N; Lakho T
Eur J Orthop Surg Traumatol; 2022 Apr; 32(3):567-574. PubMed ID: 34050817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]